832 related articles for article (PubMed ID: 28529029)
1. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
[TBL] [Abstract][Full Text] [Related]
2. Metaplastic breast cancer: Prognostic and therapeutic considerations.
Corso G; Frassoni S; Girardi A; De Camilli E; Montagna E; Intra M; Bottiglieri L; Margherita De Scalzi A; Fanianos DM; Magnoni F; Invento A; Toesca A; Conforti F; Bagnardi V; Viale G; Colleoni MA; Veronesi P
J Surg Oncol; 2021 Jan; 123(1):61-70. PubMed ID: 33047318
[TBL] [Abstract][Full Text] [Related]
3. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
[TBL] [Abstract][Full Text] [Related]
4. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
Li Y; Zhang N; Zhang H; Yang Q
J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes between metaplastic and triple-negative breast cancer patients.
Polamraju P; Haque W; Cao K; Verma V; Schwartz M; Klimberg VS; Hatch S; Niravath P; Butler EB; Teh BS
Breast; 2020 Feb; 49():8-16. PubMed ID: 31675684
[TBL] [Abstract][Full Text] [Related]
6. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
[TBL] [Abstract][Full Text] [Related]
7. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of metaplastic breast carcinoma: A single-center experience.
Ertas G; Başal FB; Üçer AR; Benzer E; Altundağ MB; Demirci U; Çetin B; Karatas F
J Cancer Res Ther; 2020; 16(6):1229-1234. PubMed ID: 33342778
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors.
Djomehri SI; Gonzalez ME; da Veiga Leprevost F; Tekula SR; Chang HY; White MJ; Cimino-Mathews A; Burman B; Basrur V; Argani P; Nesvizhskii AI; Kleer CG
Nat Commun; 2020 Apr; 11(1):1723. PubMed ID: 32265444
[TBL] [Abstract][Full Text] [Related]
10. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
[TBL] [Abstract][Full Text] [Related]
11. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment.
Aydiner A; Sen F; Tambas M; Ciftci R; Eralp Y; Saip P; Karanlik H; Fayda M; Kucucuk S; Onder S; Yavuz E; Muslumanoglu M; Igci A
Medicine (Baltimore); 2015 Dec; 94(52):e2341. PubMed ID: 26717372
[TBL] [Abstract][Full Text] [Related]
13. Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07).
Yu JI; Choi DH; Huh SJ; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Kim JH; Cho J; Kim IA; Lee JH; Park W
Clin Breast Cancer; 2015 Apr; 15(2):e105-15. PubMed ID: 25459069
[TBL] [Abstract][Full Text] [Related]
14. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
16. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
17. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
18. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
19. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]